Toxicity Evaluation of a Novel Rapamycin Liposomal Formulation After Subconjunctival and Intravitreal Injection

Salas-Ambrosio, Pedro Javier; Bernad‐Bernad, María Josefa; Linares-Alba, Mónica Anayántzin; García-Santisteban, Rodrigo; Tonix-Aburto, Luis Angel; Ornelas-Lobato, Guadalupe Jocelyn; Gracia-Mora, Isabel; Rivera-Huerta, Marisol; Sánchez-Bartéz, Francisco; Rico-Morales, Héctor; García-Sánchez, Gustavo Adolfo

doi:10.1089/jop.2020.0108

Cited by 5 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These medications include vancomycin, tobramycin, ganciclovir, fluconazole, brinzolamide, triamcinolone acetonide, and cyclosporine A. Drug-loaded liposomal formulations injected intravitreally have a number of benefits. Some benefits include lengthening the half-life of drugs [ 317 ], safeguarding labile compounds [ 318 ], and prolonging the time that liposomes spend in the tissues of the eye [ 319 ].…”

Section: Overview Of Ocular Delivery Systemsmentioning

confidence: 99%

Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases

et al. 2023

View full text Add to dashboard Cite

Chronic ocular diseases can seriously impact the eyes and could potentially result in blindness or serious vision loss. According to the most recent data from the WHO, there are more than 2 billion visually impaired people in the world. Therefore, it is pivotal to develop more sophisticated, long-acting drug delivery systems/devices to treat chronic eye conditions. This review covers several drug delivery nanocarriers that can control chronic eye disorders non-invasively. However, most of the developed nanocarriers are still in preclinical or clinical stages. Long-acting drug delivery systems, such as inserts and implants, constitute the majority of the clinically used methods for the treatment of chronic eye diseases due to their steady state release, persistent therapeutic activity, and ability to bypass most ocular barriers. However, implants are considered invasive drug delivery technologies, especially those that are nonbiodegradable. Furthermore, in vitro characterization approaches, although useful, are limited in mimicking or truly representing the in vivo environment. This review focuses on long-acting drug delivery systems (LADDS), particularly implantable drug delivery systems (IDDS), their formulation, methods of characterization, and clinical application for the treatment of eye diseases.

show abstract

Section: Overview Of Ocular Delivery Systemsmentioning

confidence: 99%

Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Next, liposomes did not cause retinal inflammation or vitreous turbidity after liposome injection. A recent study on the ocular toxicity of liposomes was carried out by Salas et al (Salas-Ambrosio, Bernad-Bernad et al, 2021). They assessed the subacute toxicity of subconjunctival and vitreous cavity injections of liposomes in New Zealand rabbits, by metabolic, histopathological and biochemical analyses.…”

Section: Liposomesmentioning

confidence: 99%

Nanoparticles in ocular applications and their potential toxicity

Cao

Yang

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Nanotechnology has been developed rapidly in recent decades and widely applied in ocular disease therapy. Nano-drug delivery systems overcome the bottlenecks of current ophthalmic drug delivery and are characterized with strong biocompatibility, stability, efficiency, sustainability, controllability, and few side effects. Nanoparticles have been identified as a promising and generally safe ophthalmic drug-delivery system based on the toxicity assessment in animals. Previous studies have found that common nanoparticles can be toxic to the cornea, conjunctiva, and retina under certain conditions. Because of the species differences between humans and animals, advanced in vitro cell culture techniques, such as human organoids, can mimic the human organism to a certain extent, bringing nanoparticle toxicity assessment to a new stage. This review summarizes the advanced application of nanoparticles in ocular drug delivery and the potential toxicity, as well as some of the current challenges and future opportunities in nanotoxicological evaluation.

show abstract